Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
Live: LIVE: Bajar Gupshup
Budget 2023
Budget 2023
you are here: HomeNewsTrendsHealth

Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient

The price for US private insurance companies will be $520 per vial, the drugmaker said, which equates to $3,120 per patient for a treatment course using 6 vials of remdesivir.

June 30, 2020 / 09:51 PM IST

Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, it said on Monday, as it set the price for a single vial at $390.

The price for US private insurance companies will be $520 per vial, the drugmaker said, which equates to $3,120 per patient for a treatment course using 6 vials of remdesivir.

Also read: Remdesivir approvals expedited, but potential COVID-19 drug unlikely to be available this month

This is below the $5,080 per course recommendation by US drug pricing research group, the Institute for Clinical and Economic Review, last week.